Uncategorized

Biogen’s targeted ALS treatment is reversing decline in some patients. Can more be helped?

Published

on

Three years after Qalsody was approved by the FDA as the first drug to target a genetic cause of ALS, some patients are reporting not only disease stabilization but also improvement of symptoms.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version